TechCelerator Grad Hopes to Commercialize Cure for Prevalent Disease
UNIVERSITY PARK, PA — Dr. Andrew Patterson and his team are taking on a potentially silent killer that plagues nearly a third of Americans. His team is Heliome Biotech, and with a market that broad, the startup's potential impact is massive.
Patterson formed Heliome Biotech in the fall of 2015 with the goal of commercializing technology that combats non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NAFLD is often asymptomatic and goes undetected, but it can lead to more serious complications.
"Fatty liver disease is a growing problem," said Patterson, "so the applications of our technology are widespread." In NASH, the fatty liver becomes inflamed and damaged, with the possibility of progression into fibrosis, liver failure and cirrhosis, ultimately requiring transplantation.
Read more: TechCelerator Grad Hopes to Commercialize Cure for Prevalent Disease